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Abstract
Visual hallucinations are a common symptom of Parkinson’s disease dementia. 
These can cause delusions and violent behaviors that can be significant burdens on 
patients and caregivers. The cause of visual hallucinations is considered to be the 
dysregulation of the default mode network due to the presence of Lewy bodies  
in the cortex and the degeneration of dopaminergic and cholinergic neurons. 
Dopaminergic agents, especially non-ergoline dopamine agonists, can exacerbate 
visual hallucinations. Reducing the dosage can ameliorate symptoms in many cases; 
however, this frequently worsens parkinsonism. In contrast, the administration 
of cholinesterase inhibitors is effective and rarely worsens motor symptoms. In 
advanced cases, antipsychotic drugs are required; clinical studies have shown that 
some drugs are beneficial while the adverse events are acceptable. An optimal treat-
ment protocol should be selected depending on the patient’s condition.
Keywords: Parkinson’s disease, dementia, hallucinations, dopaminergic agents, 
cholinesterase inhibitors, antipsychotic agents
1. Introduction
Advanced Parkinson’s disease (PD) patients often have dementia due to 
widespread Lewy bodies in the cerebrum [1]. Lewy bodies are inclusion bodies 
consisting of a protein, named alpha-synuclein [2]. In Parkinson’s disease dementia 
(PDD), visual hallucinations (VH), defined as hallucinations accompanied by delu-
sions, which are abnormal beliefs that are endorsed by patients as real, that persist 
in spite of evidence to the contrary, and that are not part of a patient’s culture or 
subculture, are a common symptom as in dementia with Lewy bodies (DLB) [3]. 
VH can cause delusions and violent behavior that can be a considerable burden on 
patients and their caregivers [4–6]; therefore, optimal treatments are indispensable.
In the early stages of PD, VH are usually a simple presentation like blurred 
moving images [3]. Complex VH, which are consisting of well-organized unreal 
visual perception, appear as the disease progresses. In a study of early-stage patients 
within 7 years from onset, VH were found in 17% during 4-year follow-up [7]. On 
the other hand, the lifetime incidence was reported as 50% [8].
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The main form of treatment is the adjustment of medication dosage. In many 
cases, a reduction of the dose of dopaminergic agents ameliorates symptoms [2]. In 
contrast, the administration of antidementia medications, especially cholinesterase 
inhibitors, is an effective alternative that can relieve VH without worsening motor 
symptoms [2]. However, antipsychotic agents are required for some patients [2]. In 
this chapter, we review previous studies on drug management to propose a clinical 
approach for treating VH in PDD patients.
2. Etiology of visual hallucinations
Visual identification of objects processes from the occipital lobes to the temporal 
lobes [9]. The object is recognized when this visual information is linked to memo-
ries. It is considered that this linking occurs partly in a network called the default 
mode network (DMN) [3, 10]. The DMN is activated when a person does not focus 
on any task in particular [3, 11]. The DMN comprises multiple parts of the brain 
such as the medial prefrontal cortex, precuneus, posterior cingulate cortex, inferior 
parietal cortex, and lateral temporal cortex (Figure 1) [12]. In contrast, the network 
activated by attention-demanding tasks is called the task-positive network (TPN) 
[3, 11], which includes the lateral frontal cortex, superior parietal cortex, insula 
cortex, and frontal operculum cortex [12]. The TPN modulates the DMN, and it is 
hypothesized that overactivity of the DMN causes VH (Figure 2) [3].
Findings from a pathological study are consistent with this hypothesis. One 
study compared Lewy body deposits in patients with and without VH [13]. Patients 
with VH had more accumulation of Lewy bodies at many sites, and the most statis-
tically significant difference was seen in the frontal cortex. Most of this area is part 
of the TPN, and the damage incurred by Lewy bodies can lead to the dysregulation 
of the DMN.
Furthermore, dopaminergic and cholinergic agents can affect VH [14]. 
Dopaminergic neurons and cholinergic neurons are associated with visual recognition. 
The prefrontal cortex and striatum receive dopaminergic stimulation and control 
attention and working memory [15–19]. The nucleus basalis of Meynert projects ace-
tylcholine across the entire cerebral cortex [20]. These are related to the TPN; there-
fore, dopaminergic or cholinergic dysfunction can cause dysregulation of the DMN.
Although the pathophysiology of VH is not fully understood, it is reasonable to 
adjust dopaminergic agents and administer antidementia drugs to treat VH of PDD 
patients.
Figure 1. 
DMN components. DMN is mainly composed of the medial prefrontal cortex, precuneus, posterior cingulate 
cortex, inferior parietal cortex, and lateral temporal cortex.
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3. Management of dopaminergic agents
Most PDD patients with VH use dopaminergic agents (e.g., levodopa, dopamine 
agonists, monoamine oxidase inhibitors, catechol-O-methyltransferase inhibi-
tors, or amantadine) to ameliorate motor symptoms. However, these drugs may 
exacerbate VH in patients with PDD [14]. This exacerbation is considered to be due 
to the overactivity of the mesolimbic system caused by an unnatural dopaminergic 
stimulation. Of course, other drugs, such as anticholinergics, antidepressants, and 
N-methyl-D-aspartate (NMDA) antagonists, can cause VH; however, these are less 
frequently used, and most of them have a low risk [3, 14]. Thus, reducing the dose 
of dopaminergic agents ameliorates the symptoms of VH.
Not all patients require VH treatment since, in some mild cases, patients can 
understand that VH are unreal. In such cases, motor symptom treatment is priori-
tized; therefore, dopaminergic agents can be continued. Goetz et al. evaluated the 
prognosis of PD patients who have VH with insight [21]. Eighty-one percent of the 
patients progressed to VH without insight during 3-year follow-up (Figure 3). If VH 
cause delusions or violent behavior, doses of dopaminergic agents should be reduced. 
However, abruptly discontinuing them can cause severe rigidity and rhabdomyolysis, 
possibly leading to neuroleptic malignant syndrome [22, 23]; thus, gradual tapering 
is recommended.
Among dopaminergic agents, non-ergoline dopamine agonists pose a greater 
risk of VH than do others [24], which have different dopamine receptor binding 
profiles compared with dopamine [25]. It is considered that this profile differ-
ence causes VH. Four non-ergoline dopamine agonists, pramipexole, ropinirole, 
rotigotine, and apomorphine, received U.S. Food and Drug Administration (FDA) 
approval as PD treatment agents and are globally used. In PDD patients with VH 
using these drugs, a reduction in the dose is recommended. In particular, slow 
tapering is strongly recommended to avoid dopamine agonist withdrawal syn-
drome [26]. This syndrome can cause miscellaneous symptoms, such as anxiety, 
Figure 2. 
Brain network process of linking visual input to memories. DMN properly links visual information input to 
memories under regulation by TPN (A). DMN links visual information input to inappropriate memories 
without adequate regulation by TPN (B).
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depression, irritability, fatigue, nausea, pain, and suicidal ideation [27, 28]. 
Careful monitoring is required after reducing drug dosage, since patients can show 
symptoms even during slow tapering [27, 29].
Reducing dopaminergic agents worsens motor symptoms in most cases. Since 
most PDD patients are in the advanced disease stage, worsening bradykinesia due 
to the drug reduction can lead to fatal complications such as pneumonia [30]. 
Therefore, it may be necessary to change from a high-risk drug to a relatively safe 
drug rather than merely reduce it (e.g., non-ergoline dopamine agonist replace-
ment by levodopa). However, all dopaminergic agents can cause VH [3, 14], and 
deterioration of motor functions may be unavoidable in some cases. This is a 
trade-off situation, and it is necessary to comprehensively consider the balance of 
all symptoms and adjust the optimal prescription for each patient [31].
4. Therapeutic drugs
4.1 Overview of therapeutic drugs
Several studies have reported the therapeutic effects of antidementia and 
antipsychotic drugs on VH. There are two types of globally used antidementia 
drugs, cholinesterase inhibitors and NMDA receptor antagonists. We reviewed key 
previous studies on these drugs.
Figure 3. 
Three-year follow-up result of PD patients who had VH with insight [21]. Eighty-one percent of the patients 
progressed to VH without insight. Fifteen percent reduced PD medication and retained insight.
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Cholinesterase inhibitors reduce VH and mostly do not worsen parkinsonism 
[32–43]. They can be used as first-line drugs. Although there is no study showing 
that memantine ameliorates VH sufficiently, it may improve cognitive function 
[44]. It can be used as an additional drug. Antipsychotic drugs should be used in a 
minimal dose due to high risks of mortality and adverse events [45]. However, some 
of them reduce VH without causing intolerable adverse events [46, 47]. They should 
be used for cases that are difficult to control.
Hereafter, we will explain the studies on and detailed characteristics of these 
drugs and propose a treatment strategy.
4.2 Cholinesterase inhibitors
Previous studies have revealed that PDD patients have cholinergic deficits [48]. 
Alpha-synuclein pathology usually occurs in the nucleus basalis of Meynert, which 
projects acetylcholine throughout the cerebral cortex [20]. This can cause TPN 
dysfunction leading to VH [49]. Cholinesterase inhibitors ameliorate cognitive 
functions and reduce VH in PDD and DLB patients [32–43]. They rarely worsen 
parkinsonism. Research has been conducted on three agents: rivastigmine, done-
pezil, and galantamine. These drugs are clinically used in North America, Latin 
America, Europe, the Middle East, Asia, and Oceania.
Rivastigmine was the first cholinesterase inhibitor that showed a reduction in 
VH in DLB patients in a randomized controlled trial (RCT) [36]. It not only inhibits 
acetylcholinesterase but also suppresses butyrylcholinesterase [50]. It was sug-
gested that this dual inhibition may be beneficial for the long-term treatment of 
Alzheimer’s disease (AD) [51, 52]. As half of the PDD patients have AD pathology 
[53], this pharmacological characteristic may also be preferable for PDD treatment. 
A large double-blind RCT suggested that rivastigmine ameliorates VH as well as 
cognitive function in PDD patients [39]. In this study, significant improvements 
in both neuropsychiatric inventory (NPI) and mini-mental state examination 
(MMSE) scores were observed. Although it caused a significantly high frequency of 
gastrointestinal adverse events, a transdermal patch is available [54], which is less 
likely to cause gastrointestinal events [55]. Another study compared rivastigmine 
effect on PDD patients with and without VH [42]. The cognitive function improve-
ment was greater in patients with VH. These previous studies suggest rivastigmine 
is beneficial for PDD patients with VH.
Donepezil is a selective acetylcholinesterase inhibitor and delays the hydrolysis 
of acetylcholine in the brain neuronal synapses [56]. Stinton et al. performed a sys-
tematic review and meta-analysis of donepezil studies for PDD patients [32]. They 
compared MMSE scores between donepezil and placebo groups in four double-
blind RCTs [34, 38, 41, 43]. Donepezil group showed better scores, but without 
significant difference. They found significantly better scores of NPI [38, 41], which 
suggests a possibly beneficial effect of donepezil on VH. The most frequent adverse 
event was gastrointestinal symptoms [34, 38, 41, 43]. In the largest study, 21% of 
the donepezil group patients experienced nausea, and the frequency was signifi-
cantly higher than in the placebo group [41]. However, no discontinuation rate dif-
ference was found. Mori et al. performed a double-blind RCT of donepezil for DLB 
patients [35]. In this study, the experimental group had fewer VH and significant 
improvement of NPI. Furthermore, a positron emission tomography study showed 
a significant change of glucose metabolism in occipital lobes after administration 
of donepezil [33]. Although we need to be aware of the side effects, donepezil is a 
reasonable choice for VH treatment. We have summarized the RCTs of donepezil in 
Table 1.
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Galantamine is another acetylcholinesterase inhibitor commonly used. It is 
also an allosteric potentiating ligand for nicotinic acetylcholine receptors [56, 57]. 
(The pharmacological characteristics of each cholinesterase inhibitor are described 
in Figure 4.) We did not find a double-blind RCT for galantamine. However, a 
small open-label controlled trial showed significant amelioration of VH, as well as 
MMSE and NPI scores [37]. The drug-related adverse events were seen in 30% of 
the experimental group, and the most frequent one was drooling. Edwards et al. 
performed a 24-week open-label study on DLB patients [40]. This study suggested 
that galantamine ameliorates VH similar to rivastigmine and donepezil in DLB 
patients. Galantamine is a possible option in PDD patients with VH, based on these 
studies.
Cholinesterase inhibitors generally ameliorate VH without worsening motor 
symptoms. Each of them has a different advantage, and they should as such be 
selected depending on the patient’s condition. Donepezil is the most clinically 
studied drug, and its efficacy is reliable [34, 38, 41, 43]. Besides, the administration 
burden is small since it requires oral intake only once a day due to its long elimina-
tion half-life [58]. In contrast, galantamine requires oral administration twice daily 
[59]. However, it can ameliorate agitation and disinhibition due to its nicotinic 
effect [60]. The most remarkable benefit of rivastigmine is the availability of the 
transdermal patch [54]. It can be administered to patients who refuse oral intake.
4.3 Memantine
Memantine is an antidementia drug that blocks NMDA receptors [61]. It is 
approved for clinical use in North America, Latin America, Europe, the Middle 
East, Asia, and Oceania. Many RCTs and meta-analytic studies have demonstrated 
the beneficial effect of memantine in AD patients [62–66]. In contrast, according 
to a meta-analysis of three RCTs of PDD and DLB patients, no significant ameliora-
tion of cognitive function or VH was found [32, 67–69]. However, another meta-
analysis reported a small but significant improvement in the score of clinicians’ 
Authors Year Patients Protocol Improved primary outcome
Aarsland 
et al. [43]







Mini-mental state examination 
and clinician’s interview-based 








None (not significant trend 





















impression of change plus 
caregiver input scale
Each study did not show the beneficial effect of donepezil on VH. However, Stinton’s systematic review showed 
significantly better NPI scores, which suggested that donepezil possibly ameliorates VH [32].
Table 1. 
RCTs of donepezil on PDD or PD patients with cognitive impairment.
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global impression of change [44]. Memantine has very few drug-related adverse 
events [67–69], and it can be used as an additional treatment for cognitive func-
tion improvement. However, findings from a case series suggested that memantine 
may exacerbate VH [70]. As other NMDA antagonists, such as ketamine, can cause 
hallucinations, memantine may have a similar effect [3]. Although the evidence 
suggesting exacerbation of VH is limited with most RCTs reporting no significant 
deterioration [67–69], memantine should be used with caution.
4.4 Antipsychotic agents
Antipsychotic agents compromise dopaminergic function and ameliorate 
psychiatric symptoms including VH. They should be used in a minimal dose owing 
to high risks of mortality and adverse events in these patients [45]. However, several 
studies have reported the beneficial effect of atypical antipsychotic agents.
A systematic review suggested that clozapine is efficacious in the treatment of 
psychosis in PD patients [46]. Two double-blind placebo-controlled RCTs were 
performed, and both studies showed significant amelioration of psychosis without 
worsening of motor symptoms [71, 72]. One of them showed significant allevia-
tion of VH [72]. However, in a 12-week open-label extension study of these RCTs, 
one withdrawal out of 108 patients due to leukocytopenia was registered [73, 74]. 
Clozapine leukocytopenia can be fatal, and weekly blood sampling is required for 
several months according to each country’s regulation [75]. In addition, it may cause 
myocarditis and hyperglycemia [76, 77]. Therefore, clozapine is clinically useful but 
requires monitoring.
Figure 4. 
The pharmacological characteristics of each cholinesterase inhibitor. Rivastigmine, donepezil, and galantamine 
inhibit acetylcholinesterase. Rivastigmine also suppresses butyrylcholinesterase. Galantamine binds to the 
nicotinic receptors and allosterically enhances their response to acetylcholine.
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Quetiapine is possibly useful for VH in PD patients, but the evidence is insuf-
ficient [46]. Five double-blind placebo-controlled RCTs were performed [78–82]. 
No significant amelioration of psychiatric symptoms was demonstrated in four 
studies [78–81]. However, one study showed significant improvement of the clinical 
global impression scale and the hallucination item of the brief psychiatric rating 
scale scores [82]. In addition, two RCTs compared effects of quetiapine and clozap-
ine, and both were almost equally effective on psychosis [83, 84]. No worsening of 
motor symptoms was seen in all of these studies. Quetiapine is possibly beneficial 
for PDD patients with VH. However, it should be used cautiously because it is asso-
ciated with risks of arrhythmia and hyperglycemia [85, 86]. We have summarized 
the quetiapine studies in Table 2.
Pimavanserin is a serotonin 5-HT2A agonist without dopaminergic affinity [87]. 
A systematic review reported it effective in the treatment of PD psychosis [46], 
and it is the only drug that has FDA approval for the PD psychosis treatment. A 
double-blind, placebo-controlled RCT showed significantly better amelioration of 
VH and other psychiatric symptoms compared with that in the placebo group [88]. 
A subgroup analysis revealed that it was also efficacious and safe for cognitively 
impaired patients; therefore, it may be useful for PDD patients [89]. However, ten 
out of 105 experimental patients discontinued the treatment due to adverse events. 
Six of these patients experienced psychosis. In addition, pimavanserin may prolong 
the QT interval, and thus, it should not be used in patients with arrhythmias [90]. 
Pimavanserin administration requires caution and careful monitoring for psychiat-
ric adverse events.
Other antipsychotic agents (e.g., olanzapine, risperidone, or aripiprazole) lack 
evidence of the beneficial effect on VH or other psychiatric symptoms. If other 
antipsychotic agents, especially typical ones, are required, they should be adminis-
tered for as short a period as possible.
Authors Year Patients Protocol Main outcome
Morgante  
et al. [84]
2004 45 PD patients 
with psychosis
Randomized rater-blinded 
















2006 27 PD patients 
with psychosis
Randomized rater-blinded 
prospective comparison with 
clozapine
Significantly less 




2007 40 patients with 





























better VH status in 
quetiapine group
The clinical evidence of quetiapine’s beneficial effect on PD patients is not sufficient because most RCTs did not show 
preferable results.
Table 2. 
Studies of quetiapine on PD patients.
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4.5 Treatment strategy
In mild cases, the administration of cholinesterase inhibitors is the first 
option. When VH are troublesome, modification of dopaminergic agent is 
recommended. If VH are not controlled by dopaminergic agent modification and 
cholinesterase inhibitors, antipsychotic agents are recommended. We propose a 
treatment plan in light of these findings (Figure 5). The optimal treatment will 
be different for each patient and should be selected depending on the patient’s 
condition.
5. Conclusion
VH are a frequent symptom in PDD. The lifetime incidence was reported as 
50% [8]. VH can cause delusions and violent behavior that can be a considerable 
burden on patients and their caregivers [4–6]; therefore, optimal treatments are 
indispensable.
Figure 5. 
Flowchart for management of PD patients with VH. Optimal education about VH can ameliorate the 
behavioral symptoms in some patients. The need for medical treatment depends on whether VH are 
troublesome after behavioral interventions. However, if VH do not cause problems, it can worsen in the disease 
course and must be monitored.
Dementia in Parkinson’s Disease
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The cause of VH is hypothesized to be linked to the overactivity of the DMN [3]. 
Dopaminergic or cholinergic dysfunction is associated with dysregulation of the 
DMN. It is reasonable to adjust dopaminergic agents and administer antidementia 
drugs to treat the VH of PDD patients.
Reducing dopaminergic drug dosage can ameliorate symptoms [2]. However, 
this frequently worsens motor symptoms. The administration of cholinesterase 
inhibitors is effective and rarely worsens parkinsonism [2].
Antipsychotic agents should be used in a minimal dose because of adverse events 
[45]. However, several studies have reported that clozapine and pimavanserin can 
ameliorate VH without worsening motor symptoms [46]. Although there is not 
sufficient evidence, quetiapine is possibly useful too [46].
An optimal treatment plan should be selected depending on the patient’s 
condition.
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